ECSP055524A - Derivados de indolin-fenilsufonamida - Google Patents

Derivados de indolin-fenilsufonamida

Info

Publication number
ECSP055524A
ECSP055524A EC2005005524A ECSP055524A ECSP055524A EC SP055524 A ECSP055524 A EC SP055524A EC 2005005524 A EC2005005524 A EC 2005005524A EC SP055524 A ECSP055524 A EC SP055524A EC SP055524 A ECSP055524 A EC SP055524A
Authority
EC
Ecuador
Prior art keywords
derivatives
indolin
phenylsufonamide
dyslipidemias
prophylaxis
Prior art date
Application number
EC2005005524A
Other languages
English (en)
Inventor
Hilmar Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP055524A publication Critical patent/ECSP055524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de indolin-fenilsulfonamida sustituidos, a procedimientos para su preparación así como a su uso en medicamentos, especialmente como compuestos que activan el PPAR-delta potentes para la profilaxis y/o tratamiento de enfermedades cardiovasculares, especialmente de las dislipidemias y enfermedades cardíacas coronarias.
EC2005005524A 2002-07-03 2005-01-03 Derivados de indolin-fenilsufonamida ECSP055524A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10229777A DE10229777A1 (de) 2002-07-03 2002-07-03 Indolin-Phenylsulfonamid-Derivate

Publications (1)

Publication Number Publication Date
ECSP055524A true ECSP055524A (es) 2005-03-10

Family

ID=29796112

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005524A ECSP055524A (es) 2002-07-03 2005-01-03 Derivados de indolin-fenilsufonamida

Country Status (26)

Country Link
US (1) US20060100230A1 (es)
EP (1) EP1519919A1 (es)
JP (1) JP2005535649A (es)
CN (1) CN1678581A (es)
AR (1) AR040352A1 (es)
AU (1) AU2003246638A1 (es)
BR (1) BR0312549A (es)
CA (1) CA2491477A1 (es)
DE (1) DE10229777A1 (es)
EC (1) ECSP055524A (es)
GT (1) GT200300135A (es)
HN (1) HN2003000196A (es)
HR (1) HRP20050108A2 (es)
IL (1) IL165924A0 (es)
MA (1) MA27316A1 (es)
MX (1) MXPA05000133A (es)
MY (1) MY134641A (es)
NO (1) NO20050579L (es)
NZ (1) NZ537486A (es)
PE (1) PE20040645A1 (es)
RU (1) RU2328485C2 (es)
TW (1) TW200418794A (es)
UA (1) UA79003C2 (es)
UY (1) UY27878A1 (es)
WO (1) WO2004005253A1 (es)
ZA (1) ZA200500013B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335450A1 (de) * 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
DE10337839A1 (de) * 2003-08-18 2005-03-17 Bayer Healthcare Ag Indolin-Derivate
EA200600372A1 (ru) * 2003-09-05 2006-08-25 Ньюроджин Корпорейшн Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1)
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
CN101421258B (zh) * 2004-10-29 2013-08-21 凯利普西斯公司 作为ppar调节剂的磺酰基取代的双环化合物
RU2384576C2 (ru) * 2004-10-29 2010-03-20 Калипсис, Инк Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar
RU2007131501A (ru) * 2005-01-18 2009-02-27 Новартис АГ (CH) Способы применения двойных агонистов ppar и устройств для доставки лекарственных средств, содержащих такие соединения
DE102005020229A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE102005020230A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
FR2886293B1 (fr) 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
FR2890072A1 (fr) 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
TWI315304B (en) * 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
EP2288607B1 (en) * 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
NZ589694A (en) 2008-06-09 2012-05-25 Sanofi Aventis Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
RU2014149136A (ru) * 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP3027616B1 (en) * 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110483509B (zh) * 2019-09-04 2020-08-25 温州大学 一种合成含氮杂环衍生物的方法
CN110627785B (zh) * 2019-09-19 2021-06-25 温州大学 一种1,5-四氢萘啶衍生物的制备方法
CN115087657B (zh) * 2019-12-18 2025-01-21 加利福尼亚大学董事会 Lin28抑制剂和其使用方法
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
TW202220958A (zh) * 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑
CN114702448A (zh) * 2021-09-30 2022-07-05 西南大学 环烯烃的三氟甲基化串联环化螺环化合物的合成方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
KR100266467B1 (ko) * 1995-09-27 2000-10-02 우에노 도시오 설폰아미드 유도체
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
JP4790969B2 (ja) * 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤

Also Published As

Publication number Publication date
RU2005102592A (ru) 2005-07-10
EP1519919A1 (de) 2005-04-06
GT200300135A (es) 2004-03-17
WO2004005253A1 (de) 2004-01-15
HRP20050108A2 (hr) 2006-04-30
NO20050579L (no) 2005-02-02
UY27878A1 (es) 2004-02-27
TW200418794A (en) 2004-10-01
JP2005535649A (ja) 2005-11-24
IL165924A0 (en) 2006-01-15
BR0312549A (pt) 2005-04-26
HN2003000196A (es) 2004-11-22
UA79003C2 (en) 2007-05-10
ZA200500013B (en) 2006-03-29
AU2003246638A1 (en) 2004-01-23
CA2491477A1 (en) 2004-01-15
PE20040645A1 (es) 2004-10-29
MY134641A (en) 2007-12-31
MA27316A1 (fr) 2005-05-02
US20060100230A1 (en) 2006-05-11
DE10229777A1 (de) 2004-01-29
MXPA05000133A (es) 2005-04-11
RU2328485C2 (ru) 2008-07-10
CN1678581A (zh) 2005-10-05
AR040352A1 (es) 2005-03-30
NZ537486A (en) 2006-07-28

Similar Documents

Publication Publication Date Title
UY27878A1 (es) Derivados de indolinfenilsulfonamida
HN2004000146A (es) Dihidroquinazolinas sustituidas
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
UY27491A1 (es) Derivados de ácido acético
UY27939A1 (es) Compuestos
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ATE453642T1 (de) Substituierte phenylaminopyrimidine
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
UY28945A1 (es) Derivados de pirrolopiridina
UY26951A1 (es) Derivados de ácido propiónico
UY28313A1 (es) Nonadepsipeptidos acilados
UY28115A1 (es) Derivados del acido isoftalico
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
UY29127A1 (es) Nuevos derivados de pirimidina y su uso
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
UY27733A1 (es) Derivados de ciclopenteno.
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
DOP2003000663A (es) Derivados de indolinfenilsulfonamida
PA8579401A1 (es) Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b
DOP2001000260A (es) Derivados de acido propinoico